Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.535 USD | +4.75% | +14.09% | +96.09% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 158M 216M |
---|---|---|---|---|---|
Net income 2024 * | -33M -45.05M | Net income 2025 * | -46M -62.8M | EV / Sales 2024 * | - |
Net cash position 2024 * | 94.2M 129M | Net cash position 2025 * | 50.8M 69.35M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.77
x | P/E ratio 2025 * |
-3.97
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Regulus Therapeutics Inc.
1 day | +4.75% | ||
1 week | +14.09% | ||
Current month | -12.85% | ||
1 month | -10.36% | ||
3 months | +99.21% | ||
6 months | +100.80% | ||
Current year | +96.09% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 19-08-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 17-05-31 |
David Baltimore
BRD | Director/Board Member | 86 | 08-12-31 |
Director/Board Member | 75 | 13-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 2.51 | +3.72% | 74 186 |
24-04-26 | 2.42 | +6.61% | 204,765 |
24-04-25 | 2.27 | +2.25% | 97,798 |
24-04-24 | 2.22 | -1.77% | 91,807 |
24-04-23 | 2.26 | +2.73% | 101,587 |
Delayed Quote Nasdaq, April 29, 2024 at 11:34 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.09% | 158M | |
-2.63% | 103B | |
+1.66% | 95.28B | |
+1.46% | 22.15B | |
-15.25% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.43% | 16.05B | |
+4.58% | 13.68B | |
+35.44% | 12.17B |
- Stock Market
- Equities
- RGLS Stock